- Esophageal schwannomas: A rarity beneath benign esophageal tumors a case report. [Journal Article]
- IJInt J Surg Case Rep 2019 Apr 18; 58:220-223
- CONCLUSIONS: In general, Schwanommas are rarely found in the gastrointestinal tract (GI), while the great majority occur in the stomach, esophagic is the least common GI form of presentation.The knowledge about a new case, impacts in obtaining more information about the clinical course and surgical treatment of this tumor.
- [CLINICAL AND ENDOSCOPIC CHARACTERISTICS OF THE GASTRODUODENAL MUCOSAL LESIONS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION WITH DIFFERENT BODY MASS STATUS]. [Journal Article]
- GMGeorgian Med News 2019; (288):73-77
- The high prevalence and incidence of the chronic hepatitis C infection (CHC) is associated with the considerable medical and social problems, development of variety of clinical signs, hepatic and ext…
The high prevalence and incidence of the chronic hepatitis C infection (CHC) is associated with the considerable medical and social problems, development of variety of clinical signs, hepatic and extrahepatic lesions. Due to the wide spread of this infection, there is a high comorbidity with other diseases of the gastrointestinal tract, especially of its upper parts. The objective of the study was to evaluate the clinical and pathological features of mucosal lesions (ML) of the gastroduodenal zone (GDZ) and the prevalence of Helicobacter pylori infection in patients with chronic hepatitis C with different body mass status. The study included 150 patients with chronic hepatitis C. All patients underwent fibroesophagogastroduodenoscopy (FEGD), determination of Helicobacter pylori infection (H. pylori) was done by the quick urease test (CLO-test), as well as by the stool test (CITO TEST, Farmasko LLC), the intra-esophageal pH-metric test and assessment of body mass status. The Los Angeles (LA) classification (1998) was used for endoscopic assessment of the degree of esophageal damage. Depending on the body weight of the patients, two groups were formed: A group - n=35 patients with CHC with overweight (OBW) and B group, n=115 patients with CHC with normal body weight (NBW). We found that in patients with chronic hepatitis C, gastroesophageal reflux disease (GERD) is significantly more frequently registered in patients with overweight status than in those with NBW (48.6% vs. 31.3%, p<0.05). Endoscopically, in patients with chronic hepatitis C and OBW, reflux esophagitis with the LA-B degree of mucosal damage is most common (72.7%), while in patients with chronic hepatitis C and NBW the LA-A degree is most frequent (69.4%). Therefore, in patients with CHC + OBW, there are deeper ML than in patients with NBW. Our data demonstrates a high frequency of motor impairments in patients with chronic hepatitis C in the absence of erosive and ulcerative lesions of the mucosa of the GDZ, namely duodenogastric reflux with a predominance in persons with CHC + OBW against patients with CHC + NBW (47.0% vs. 13.9%, p<0.05). In patients with CHC, occurrence of the H. pylori infection is 34.7%, with no significant difference between patients with OBW and NBW. The high frequency of registered GERD and H. pylori in patients with chronic hepatitis C, indicates to the importance of the development of an optimal eradication treatment regimen that would be most effective, but at the same time, sufficiently safe and even gentle to the affected liver, taking into account the hepatotoxic effect of some proton pump inhibitors (PPIs), especially those that inhibit the activity of cytochrome P450, as well as the hepatotoxicity of some antibiotics.
- Surgeon factors are strongly correlated with who receives a sleeve gastrectomy versus a Roux-en-Y gastric bypass. [Journal Article]
- SOSurg Obes Relat Dis 2019 Mar 26
- CONCLUSIONS: While the percentage of SG in this cohort closely matches the national average, there is wide variation at the surgeon level with a significant proportion predominantly performing a single procedure. Surgeon factors are more strongly correlated with procedure selection compared to patient or hospital factors.
- The Pros and Cons of Partial Versus Total Fundoplication for Gastroesophageal Reflux Disease. [Journal Article]
- JLJ Laparoendosc Adv Surg Tech A 2019 May 17
- Laparoscopic Nissen fundoplication is currently the most commonly performed procedure for gastroesophageal reflux disease (GERD). In patients with inefficient esophageal motility, a partial fundoplic…
Laparoscopic Nissen fundoplication is currently the most commonly performed procedure for gastroesophageal reflux disease (GERD). In patients with inefficient esophageal motility, a partial fundoplication such as a Toupet 270-degree posterior fundoplication is often recommended. There is controversy as it relates to the necessity of this tailored approach to fundoplication. There is also debate when it comes to the suitability and even the superiority of a partial compared to a full fundoplication. There are numerous randomized controlled trials and meta-analyses of these trials to guide the debate. From the evidence, it would appear that a full and a partial fundoplication are associated with similar GERD-related outcomes and that a partial fundoplication is associated with fewer side effects such as bloating and dysphagia.
- Clinical Aspects of Thickeners for Pediatric Gastroesophageal Reflux and Oropharyngeal Dysphagia. [Review]
- CGCurr Gastroenterol Rep 2019 May 16; 21(7):30
- The purpose of this review is to discuss current knowledge and recent findings regarding clinical aspects of thickeners for pediatric gastroesophageal reflux and oropharyngeal dysphagia. We review ev…
The purpose of this review is to discuss current knowledge and recent findings regarding clinical aspects of thickeners for pediatric gastroesophageal reflux and oropharyngeal dysphagia. We review evidence for thickener efficacy, discuss types of thickeners, practical considerations when using various thickeners, and risks and benefits of thickener use in pediatrics.
- Phenotype of obesity and gastroesophageal reflux disease in the context of comorbidity in patients with cardiovascular diseases. [Review]
- TATer Arkh 2019 Mar 18; 91(2):126-133
- The relevance of studying such problems as gastroesophageal reflux disease (GERD) and obesity is caused by their high prevalence in the developed countries of the world. Epidemiological data indicate…
The relevance of studying such problems as gastroesophageal reflux disease (GERD) and obesity is caused by their high prevalence in the developed countries of the world. Epidemiological data indicate that obesity is a significant risk factor for developing GERD due to increased intra-abdominal pressure and gastroesophageal gradient, slowing of gastric evacuation and formation of hiatal hernia. Abdominal obesity increases the likelihood of complications of GERD: erosive esophagitis, Barrett's esophagus and adenocarcinoma. This fact is connected with humoral influences: increased production of pro-inflammatory cytokines and leptin, and decreased secretion of adiponectin. Treatment of comorbid patients requires higher dosages and longer courses of antisecretory medicines, and an additional prescription of ursodeoxycholic acid.
- Wirelessly Powered Endoscopically Implantable Devices into the Submucosa as the Possible Treatment of Gastroesophageal Reflux Disease. [Journal Article]
- GRGastroenterol Res Pract 2019; 2019:7459457
- Gastroesophageal reflux disease (GERD) is a rather common disease with a prevalence reaching up to 10 or 20% in the western world. The most specific symptoms which point to the diagnosis of GERD are …
Gastroesophageal reflux disease (GERD) is a rather common disease with a prevalence reaching up to 10 or 20% in the western world. The most specific symptoms which point to the diagnosis of GERD are feelings of heartburn and the regurgitation of acidic stomach contents into the esophagus. However, a certain number of patients do not respond to standard therapy, and in these cases, it is necessary to resort to other treatment methods, such as laparoscopic fundoplication or electrostimulation of the lower esophageal sphincter. The aim of our work was to design and manufacture a miniature, battery-less stimulator to provide electric stimulation of the lower esophageal sphincter, which could be implanted deep into the submucosa of the distal esophagus. The main goal was to provide a battery-less system as opposed to traditional battery neurostimulators to reduce the size and weight of the device. An electronic prototype of a wirelessly powered implantable device was developed. We used animal models for the experiments. The device is designed to treat GERD via electrical stimulation of the muscularis propria. It is implanted into the submucosal pocket by the lower esophageal sphincter with an endoscope. This method of implantation is superior to esophageal stimulators used today because of very low invasiveness of the surgery. Bipolar neurostimulation via two gold-plated leads is provided. The device does not have any source of energy; it is powered wirelessly which reduces the risk of potential battery leakage and reduces the overall dimensions.
- Healthcare burden among individuals with Angelman syndrome: Findings from the Angelman Syndrome Natural History Study. [Journal Article]
- MGMol Genet Genomic Med 2019 May 14; :e734
- CONCLUSIONS: This study shows that individuals with AS have high HRU/STU, and apart from a few differences, HRU/STU was similar across molecular etiology. These results reflect usage in younger individuals and studies that describe HRU/STU in older individuals are needed.
- The validation in china of a Non-Invasive salivary pepsin biomarker containing two unique human pepsin monoclonal antibodies to diagnose gastroesophageal reflux disease. [Journal Article]
- JDJ Dig Dis 2019 May 14
- CONCLUSIONS: Peptest enabled the rapid diagnosis of reflux demonstrating high pepsin sensitivity between 83% and 100% resulting in an overall sensitivity across all 9 centers of 85%, specificity 60% and positive predictive value 82%.
New Search Next
- Evaluation of symptomatic reflux esophagitis in proton pump inhibitor users. [Journal Article]
- BRBiomed Rep 2019; 10(5):277-282
- The aim of the present study was to evaluate symptomatic reflux esophagitis (RE) in proton pump inhibitor (PPI) users. The present study conducted a hospital-based, retrospective cross-sectional stud…
The aim of the present study was to evaluate symptomatic reflux esophagitis (RE) in proton pump inhibitor (PPI) users. The present study conducted a hospital-based, retrospective cross-sectional study of consecutive RE cases in PPI users at Juntendo University Hospital recruited between 2008 and 2016. Eligible patients were PPI users with a complete patient profile, who completed the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (FSSG) questionnaire, and who underwent upper gastrointestinal endoscopy for the examination of RE, hiatal hernia (HH) and endoscopic gastric mucosal atrophy (EGA). The patients with RE who were administered PPIs were divided into two groups: Those with symptomatic RE (FSSG≥8) and those with non-symptomatic RE (FSSG<8). The present study investigated the risk factors for symptomatic RE among the patients with RE patients who were administered PPIs. Of the 13,052 cases who underwent patient profiling, the FSSG questionnaire and upper gastrointestinal endoscopy, a total of 2,444 PPI users were eligible. Of the PPI users, 206 cases (8.4%) had RE. Among the 206 patients with RE, 115 (55.8%) had symptomatic RE. The profile of the symptomatic and non-symptomatic RE groups were as follows: A total of 45 females (39.1%) vs. 32 females (35.2%; non-significant); mean ± standard deviation age, 54.8±13.5 vs. 62.9±11.1 years (P<0.01); mean body mass index, 23.5±3.3 vs. 23.2±3.8 (non-significant); severe RE, 12 (10.4%) vs. 2 (2.2%; P<0.05); HH, 70 (60.9%) vs. 40 (44.0%; P<0.05); and mean score of EGA, 1.2±1.8 vs. 1.8±2.1 (P<0.05). Multivariate analysis revealed that a younger age [odds ratio (OR)=0.94; 95% confidence interval (CI): 0.92-0.97, P<0.01] and HH(+) (OR=2.37; 95% CI: 1.30-4.34, P<0.01) were associated with symptomatic RE among patients with RE who were administered PPIs. In conclusion, a younger age and HH were associated with symptomatic RE in patients with RE who were administered PPIs.